Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The disease burden of respiratory syncytial virus in older adults
Sébastien Kenmoe, Harish Nair
Current Opinion in Infectious Diseases (2024)
Open Access | Times Cited: 21

Showing 21 citing articles:

Would senior citizens get vaccinated against RSV? Exploratory analysis using a novel survey instrument
Mohammad Abu-Ghosh, D. Saleh, Joud Al-Haddad, et al.
Vacunas (2025) Vol. 26, Iss. 1, pp. 100384-100384
Open Access | Times Cited: 1
Efficacy of Respiratory Syncytial Virus Vaccination to Prevent Lower Respiratory Tract Illness in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Matteo Riccò, Antonio Cascio, Silvia Corrado, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 500-500
Open Access | Times Cited: 10
Respiratory syncytial virus infections in adults: a narrative review
Joanne Wildenbeest, David M. Lowe, Joseph F. Standing, et al.
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 10, pp. 822-836
Closed Access | Times Cited: 8
Vaccines for the Elderly and Vaccination Programs in Europe and the United States
Cleo Anastassopoulou, Stefanos Ferous, Snežana Medić, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 566-566
Open Access | Times Cited: 6
Respiratory Syncytial Virus-Attributable Hospitalizations Among Adults in High- and Middle-Income Countries: Application of the Global Burden of Disease Framework
Katrin Burkart, Quinn Rafferty, Catherine W. Gillespie, et al.
(2025)
Closed Access
Perceived benefits, information, vaccination history, and conspiracy beliefs as significant determinants of RSV vaccine acceptance among Arab seniors
Malik Sallam, Kholoud Al-Mahzoum, Zainab Mansour Yousef, et al.
Therapeutic Advances in Vaccines and Immunotherapy (2025) Vol. 13
Open Access
Molecular characterization of human Respiratory Syncytial Virus in Mexico (season 2023–2024) through whole-genome sequencing
Evelyn Rivera-Toledo, Fidencio Mejía-Nepomuceno, Enrique Mendoza-Ramírez, et al.
Research Square (Research Square) (2025)
Closed Access
Burden of Disease Due to Respiratory Syncytial Virus in Adults in Five Middle-Income Countries
Jorge A. Gómez, Otávio Cintra, Arnas Berzanskis, et al.
Infectious Disease Reports (2024) Vol. 16, Iss. 4, pp. 750-762
Open Access | Times Cited: 4
Efficacy, Safety, and Immunogenicity of the AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over Three RSV Seasons: A Randomized Trial
Michael G. Ison, Alberto Papi, Eugene Athan, et al.
(2024)
Closed Access | Times Cited: 2
A foldon-free prefusion F trimer vaccine for respiratory syncytial virus to reduce off-target immune responses
Mark J. G. Bakkers, Freek Cox, Annemart Koornneef, et al.
Nature Microbiology (2024)
Open Access | Times Cited: 2
COVID-19, Influenza, and RSV in Children and Adults: A Clinical Comparative Study of 12,000 Cases
Jae Hyun Kwon, So Hyun Paek, Soohyun Park, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 6, pp. 1702-1702
Open Access | Times Cited: 1
RSV Infection in Refugees and Asylum Seekers: A Systematic Review and Meta-Analysis
Matteo Riccò, Silvia Corrado, Marco Bottazzoli, et al.
Epidemiologia (2024) Vol. 5, Iss. 2, pp. 221-249
Open Access | Times Cited: 1
RSV Risk Profile in Hospitalized Adults and Comparison with Influenza and COVID-19 Controls in Valladolid, Spain, 2010–2022
Mariana Haeberer, Martin Mengel, Rong Fan, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 9, pp. 1983-1999
Open Access | Times Cited: 1
The tricky second album: Licensure of an mRNA vaccine for respiratory syncytial virus
John S. Tregoning
Molecular Therapy (2024) Vol. 32, Iss. 8, pp. 2428-2428
Closed Access
Aging enhances pro-atrogenic gene expression and skeletal muscle loss following respiratory syncytial virus infection
Sophie Sagawe, Verity I. P. Loake, Peter Openshaw, et al.
GeroScience (2024)
Open Access
Circulating respiratory viruses including SARS-CoV-2 during 2021-2022 season in Tunisia: Epidemiological and dynamic changes
Awatef Taktak, Saba Gargouri, Amel Chtourou, et al.
Clinical Epidemiology and Global Health (2024), pp. 101824-101824
Open Access
Enhanced susceptibility of pediatric airway epithelium to respiratory syncytial virus infection
Raymond J. Pickles, Gang Chen, Scott H. Randell
Journal of Clinical Investigation (2024) Vol. 134, Iss. 21
Open Access

Giovanna Elisa Calabrò, Caterina Rizzo, Alexander Domnich, et al.
PubMed (2024) Vol. 65, Iss. 2 Suppl 1, pp. E1-E159
Closed Access
Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options
Matteo Riccò, Bahaa Abu-Raya, Giancarlo Icardi, et al.
Vaccines (2024) Vol. 12, Iss. 12, pp. 1317-1317
Open Access
Adult respiratory syncytial virus disease burden: systematic literature review in Africa, Asia, Latin America, and the Middle East (2012–2022)
Malak Elsobky, João Leite, M.E. Mousa, et al.
Future Virology (2024), pp. 1-21
Open Access
MARCH8 Restricts RSV Replication by Promoting Cellular Apoptosis Through Ubiquitin-Mediated Proteolysis of Viral SH Protein
Takashi Okura, Tatsuki Takahashi, T Kameya, et al.
Viruses (2024) Vol. 16, Iss. 12, pp. 1935-1935
Open Access
Page 1

Scroll to top